Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic stem cell transplantation

Our previous report indicated that teicoplanin (TEIC) caused fewer adverse effects than vancomycin (VCM) in patients with febrile neutropenia (FN) receiving haematopoietic stem cell transplantation (HSCT). However, we observed breakthrough methicillin‐resistant‐Staphylococcus haemolyticus (MR‐S haemolyticus) infection during TEIC therapy in these patients. In this study, we sought to compare the incidence of breakthrough Gram‐positive cocci (GPC) infection during VCM and TEIC therapy in this population.

[1]  T. Niwa,et al.  Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation , 2019, Journal of clinical pharmacy and therapeutics.

[2]  L. Muffly,et al.  Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions , 2019, Expert review of hematology.

[3]  G. Papanicolaou,et al.  BACTERIAL BLOOD STREAM INFECTIONS (BSI), PARTICULARLY POST-ENGRAFTMENT BSI, ARE ASSOCIATED WITH INCREASED MORTALITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION , 2018, Bone Marrow Transplantation.

[4]  H. Asada,et al.  The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[5]  A. Attarbaschi,et al.  Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia , 2016, Annals of Hematology.

[6]  S. Iwata,et al.  [Practical guidelines for the management and treatment of infections caused by MRSA]. , 2013, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[7]  K. Kawa,et al.  Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia , 2013, Bone Marrow Transplantation.

[8]  K. Kawa,et al.  Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry , 2013, Bone Marrow Transplantation.

[9]  M. Fajardo-Olivares,et al.  Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. , 2011 .

[10]  F. Rodríguez-Vidigal,et al.  Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. , 2011, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

[11]  A. Mizoguchi,et al.  Investigation of the prediction accuracy of vancomycin concentrations determined by patient‐specific parameters as estimated by Bayesian analysis , 2010, Journal of clinical pharmacy and therapeutics.

[12]  J. Picazo,et al.  [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci]. , 2008, Enfermedades infecciosas y microbiologia clinica.

[13]  Esther Culebras,et al.  Actividad comparativa de la daptomicina frente a Staphylococcus aureus resistente a meticilina y frente a estafilococos coagulasa negativa , 2010 .

[14]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[15]  L. Leibovici,et al.  Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis , 2009, Antimicrobial Agents and Chemotherapy.

[16]  Guang Yang,et al.  Glycopeptides: Update on an old successful antibiotic class. , 2006, Biochemical pharmacology.

[17]  Á. Soriano,et al.  Clinical characterization of breakthrough bacteraemia: a survey of 392 episodes , 2005, Journal of internal medicine.

[18]  L. Mortin,et al.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. , 2005, The Journal of infectious diseases.

[19]  C. Walsh,et al.  Glycopeptide and lipoglycopeptide antibiotics. , 2005, Chemical reviews.

[20]  二郎 木村,et al.  グリコペプチド系抗生物質テイコプラニンのTDM解析支援ソフトウエア (TEICTDM) の開発 , 2004 .

[21]  K. Tabata,et al.  [Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic]. , 2004, The Japanese journal of antibiotics.

[22]  J. Šufliarský,et al.  Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. , 1997, Journal of medical microbiology.

[23]  S. Špánik,et al.  Breakthrough nosocomial bacteraemia due to teicoplanin-resistant Staphylococcus haemolyticus in five patients with acute leukaemia. , 1997, The Journal of hospital infection.

[24]  M. Wood,et al.  The comparative efficacy and safety of teicoplanin and vancomycin. , 1996, The Journal of antimicrobial chemotherapy.

[25]  P. Gilligan,et al.  Emergence of vancomycin resistance in coagulase-negative staphylococci. , 1987, The New England journal of medicine.

[26]  R. Pallanza,et al.  TEICOPLANIN-RESISTANT COAGULASE-NEGATIVE STAPHYLOCOCCI , 1987, The Lancet.

[27]  J. Turney,et al.  TEICOPLANIN-RESISTANT COAGULASE-NEGATIVE STAPHYLOCOCCUS , 1986, The Lancet.

[28]  D. Felmingham,et al.  TEICOPLANIN-RESISTANT COAGULASE-NEGATIVE STAPHYLOCOCCUS , 1986, The Lancet.

[29]  J. Lewis,et al.  Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance. , 1986, The Journal of infectious diseases.